Breaking News

Exelixis Acquires GamaMabs Oncology Antibody Program

Gains AMHR2 franchise technology including all assets pertaining to GamaMabs’ monoclonal antibody drug product murlentamab.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Exelixis, Inc. and GamaMabs Pharma have entered an agreement under which Exelixis will acquire all rights to GamaMabs’ AMHR2 antibody technology. Exelixis will pay GamaMabs $5 million upfront and will make additional payments upon closing and achieving certain milestones. Exelixis will control 100% of GamaMabs’ AMHR2 franchise technology including all assets pertaining to GamaMabs’ monoclonal antibody drug product murlentamab (GM-102).   “GamaMabs has generated a compelling body of preclinical...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters